Typewriter Therapeutics emerged from stealth with $56 million in Series A financing, focusing on RNA-based gene therapies aimed at patients with cancer, autoimmune disease, and severe genetic disorders. The company’s in vivo CAR-T positioning suggests a push to deliver therapeutic programs inside the body rather than relying on patient-specific cell manufacturing. The financing size and focus indicate investor interest in RNA modality approaches that could streamline access and reduce manufacturing bottlenecks typical of traditional CAR-T. Typewriter’s next step will be translating preclinical differentiation into IND-enabling packages and early clinical execution.